Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients
I. Schouten (Leiden, Netherlands), M. Kasteleyn (Leiden, Netherlands), R. Bals (Homburg/Saar, Germany), A. Turner (Birmingham, United Kingdom), I. Ferrarotti (Pavia, Italy), A. Corsico (Pavia, Italy), B. Lara Gallego (Coventry, United Kingdom), M. Miravitlles (Barcelona, Spain), R. Stockley (Birmingham, United Kingdom), J. Stolk (Leiden, Netherlands)
Source: Virtual Congress 2021 – Treatments for airway diseases
Session: Treatments for airway diseases
Session type: E-poster
Number: 1833
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Schouten (Leiden, Netherlands), M. Kasteleyn (Leiden, Netherlands), R. Bals (Homburg/Saar, Germany), A. Turner (Birmingham, United Kingdom), I. Ferrarotti (Pavia, Italy), A. Corsico (Pavia, Italy), B. Lara Gallego (Coventry, United Kingdom), M. Miravitlles (Barcelona, Spain), R. Stockley (Birmingham, United Kingdom), J. Stolk (Leiden, Netherlands). Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients. 1833
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: